FDA approves sotorasib with panitumumab for colorectal cancer
On Jan. 15, 2025, the FDA approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for KRAS G12C-mutated metastatic colorectal cancer.
Related Articles
TACE Plus Lenvatinib/Pembrolizumab Boosts PFS in Unresectable Liver Cancer
Adding lenvatinib/pembrolizumab to TACE elicits a numerical overall survival improvement in the LEAP-012 trial, although additional follow-up is necessary.
Molecular Characterization Initiative for Childhood Cancers
Learn how the CCDI Molecular Characterization Initiative aims to improve childhood cancer research, diagnosis, clinical trials, and data sharing.
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial
PURPOSETransurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive…
Cancer statistics, 2025
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data…
Stay up to date on the latest in Hematology – Hematology.org
Stay up to date on the latest in Hematology
FDA approves sotorasib with panitumumab for colorectal cancer
On Jan. 15, 2025, the FDA approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for KRAS G12C-mutated metastatic colorectal cancer.
FDA to Hold Webinar on the Updated “Healthy” Claim
Webinar on the Final Rule on the Definition of Term “Healthy” on food labels
Drug in clinical trials for breast cancer could also treat some blood cancers | WashU Medicine
Researchers are working with industry toward a clinical trial for blood cancer patients
Machine learning prediction of brain metastasis invasion pattern on brain magnetic resonance imaging scans
AbstractBackground. Brain metastasis invasion pattern (BMIP) is an emerging biomarker associated with recurrence-free and overall survival in patients, and
FDA approves acalabrutinib with bendamustine and rituximab
On January 16, 2025, the FDA granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma…